Plain-English translation of NCT06059638 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Hypertension research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing a new feature called AVIM therapy that can be programmed into certain pacemakers (the Astra/Azure model) to help lower high blood pressure. Researchers want to see if turning on this special setting—while you continue taking your regular blood pressure medications—can bring your blood pressure down more effectively than a pacemaker without this feature activated.
Many people take multiple blood pressure medications but still struggle to control their high blood pressure. This trial explores whether this treatment can offer an additional way to lower blood pressure and reduce the need for extra medications.
You likely qualify if…
You likely don't qualify if…
If you qualify, you'll be randomly assigned to either have the new AVIM therapy setting turned on or turned off in your pacemaker—you won't know which group you're in at first. You'll visit the clinic regularly over three years: a 1-year phase where the study is blinded, followed by a 2-year phase where everyone knows whether they have the therapy activated. Throughout the study, you'll continue taking your regular blood pressure medications, and researchers will monitor your blood pressure and overall health.
AI-generated summary from trial data · Jul 19, 2026 · Not medical advice
United States